Cuevas-Barragan CE, Buenrostro-Nava MT, Palos-Gómez GM, Ramirez-Padilla EA, Mendoza-Macias BI, Rivas-Caceres RR. Use of Nasoil® via intranasal to control the harmful effects of Covid-19.
Microb Pathog 2020;
149:104504. [PMID:
32950636 PMCID:
PMC7497547 DOI:
10.1016/j.micpath.2020.104504]
[Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/10/2020] [Revised: 09/10/2020] [Accepted: 09/11/2020] [Indexed: 02/07/2023]
Abstract
In the absence of vaccines and antiviral drugs available to prevent and treat COVID-19, it becomes imperative to find or use all those products with the potential to fight this virus. This article is an attempt to propose ways to prevent, treat and control the COVID-19 virus, using a product based on plant extracts with the potential to reduce the symptoms caused by the SARS-CoV-2 virus. Nasoil® counts as one of its main components, Asclepias curassavica extracts, and in the present study it has been shown that it is an effective adjuvant in the treatment of Covid-19, increasing the respiratory capacity of the patients (SpO2> 90%) and reducing the symptoms from the first application, improving the patients around the fifth to the eighth application. At a preventive level, the individuals in this study who have applied it (400 individuals) only a 3.15% of these presented symptoms, disappearing when increasing the weekly applications.
Nasoil® protects from the appearance of symptoms by 96% due to Covid-19.
Modifying lung microenvironments reduces Covid-19 symptoms.
Promoting new interactions in the elastic protein decreases the elastase activity of neutrophils.
The combination of plant extracts in Nasoil® help in respiratory problems.
Nasoil® is an co-adjuvant for the control and prevention of the SARS-CoV-2 virus.
Collapse